Inventor · disambiguated record
Franck Amblard
Also filed as: AMBLARD FRANCK
15 granted patents·9 pending applications·96 citations·filing 2011–2024
90Inventor score
Top patents by PatentIndex Score
24 records- 0195US11207370B2Peptidomimetics for the treatment of coronavirus and picornavirus infectionsUNIV EMORY·Filed 2020·Granted Dec 28, 2021·19 cites·13 claims
- 0295US8859595B2Potent and selective inhibitors of hepatitis C virusCOATS STEVEN J·Filed 2011·Granted Oct 14, 2014·31 cites·6 claims
- 0392US11021513B2Peptidomimetics for the treatment of norovirus infectionUNIV EMORY·Filed 2017·Granted Jun 1, 2021·19 cites·15 claims
- 0491US9181227B2Potent and selective inhibitors of hepatitis C virusCOCRYSTAL PHARMA INC·Filed 2014·Granted Nov 10, 2015·8 cites·5 claims
- 0589US9809616B2Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancerCOCRYSTAL PHARMA INC·Filed 2013·Granted Nov 7, 2017·15 cites·11 claims
- 0677US10752584B2Elimination of hepatitis B virus with antiviral agentsUNIV EMORY·Filed 2017·Granted Aug 25, 2020·3 cites·23 claims
- 0772US2024216414A1Antiviral Agents and Nucleoside Analogs for Treatment of Zika VirusUNIV EMORY·Filed 2024·Application pending·0 cites
- 0871US2025114389A1Nucleosides and nucleotides analogs as antiviral agentsUNIV EMORY·Filed 2022·Application pending·0 cites
- 0971US2024216413A1Thionucleosides as antiviral agentsUNIV EMORY·Filed 2022·Application pending·0 cites
- 1070US2024238323A1Modified nucleosides and nucleotides analogs as antiviral agents for corona and other virusesUNIV EMORY·Filed 2022·Application pending·0 cites
- 1166US9932326B2Potent and selective inhibitors of hepatitis C virusCOCRYSTAL PHARMA LLC·Filed 2015·Granted Apr 3, 2018·1 cites·10 claims
- 1263US12268723B2Peptidomimetics for the treatment of coronavirus and picorna virus infectionsUNIV EMORY·Filed 2021·Granted Apr 8, 2025·0 cites·4 claims
- 1360US11963972B2Antiviral agents and nucleoside analogs for treatment of Zika virusUNIV EMORY·Filed 2017·Granted Apr 23, 2024·0 cites·13 claims
- 1460US11859014B2Peptidomimetics for the treatment of Norovirus infectionUNIV EMORY·Filed 2021·Granted Jan 2, 2024·0 cites·16 claims
- 1555US11629125B2Elimination of hepatitis b virus with antiviral agentsUNIV EMORY·Filed 2020·Granted Apr 18, 2023·0 cites·9 claims
- 1654US2025339445A1Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and StrokeUNIV EMORY·Filed 2021·Application pending·0 cites
- 1745US2023056135A1Monomer and multimeric anti-hbv agentsUNIV EMORY·Filed 2019·Application pending·0 cites
- 1843US12318393B2Modulators of orphan nuclear receptors for NASH and other metabolic disordersUNIV EMORY·Filed 2019·Granted Jun 3, 2025·0 cites·14 claims
- 1941US12239655B2Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agentsSCHINAZI RAYMOND F·Filed 2018·Granted Mar 4, 2025·0 cites·22 claims
- 2041US9926295B2Potent and selective inhibitors of hepatitis C virusCOCRYSTAL PHARMA INC·Filed 2015·Granted Mar 27, 2018·0 cites·13 claims
- 2139US2017037078A12' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancerCOCRYSTAL PHARMA INC·Filed 2015·Application pending·0 cites
- 2237US2017334941A12',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancerCOCRYSTAL PHARMA INC·Filed 2015·Application pending·0 cites
- 2334US10011629B2Nucleoside analogs for treatment of the flaviviridae family of viruses and cancerCOCRYSTAL PHARMA INC·Filed 2016·Granted Jul 3, 2018·0 cites·17 claims
- 2430US2019077797A1Processes for preparing 2-dihalo ribolactonesSARI OZKAN·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →